News | Proton Therapy | October 23, 2020

IBA Highlights the Future of Proton Therapy Technologies at ASTRO 2020

IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy

IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy

October 23, 2020 — IBA, a leading provider of proton therapy solutions, will highlight how its Proteus solutions as well as its work with its partners are shaping the future of proton therapy during the Annual Meeting and exhibition of the American Society for Radiation Oncology (ASTRO) being held online October 22-29, 2020.
 
IBA is displaying the latest developments for its Proteus systems that will address the current and future needs of proton therapy centers. IBA’s comprehensive Motion Management package will help clinicians treat more indications more confidently. Additionally, IBA’s unique Proton Arc Therapy will enable clinicians to treat patients precisely, faster and more easily. Finally, IBA believes Flash Therapy using protons has the potential to radically change the radiation therapy landscape revolutionize cancer care in general.
 
With 59 centers sold and 36 centers treating patients on a daily basis, IBA has the largest and most knowledgeable proton therapy user community. Together with its clinical partners, IBA is proud to celebrate a truly significant milestone of over 100,000 patients treated on an IBA Proteus system. This unique accumulated technical and clinical expertise is openly shared within IBA’s network of users through regular user meetings, bringing together experienced users as well as new members in the IBA community.
 
Having an open vendor platform, IBA also integrates the solutions of key leading industrial partners to further improve clinical workflow, integration and the overall user experience.  
 
IBA has a long-term collaboration with Philips in imaging, diagnostics and radiation therapy for comprehensive cancer treatment.
 
The long-standing collaboration with Elekta is allowing both companies to offer a full set of treatment modalities in radiation therapy. IBA is very excited about the upcoming innovations in the Elekta Treatment Planning Solution. Together with MOSAIQ OIS and MOSAIQ Plaza, this complete solution will provide a strong ecosystem to integrate Proton Therapy into radiation therapy departments. Close collaboration with RaySearch Laboratories has demonstrates a fully integrated proton therapy workflow integrating IBA’s Proteus solution with Advanced treatment planning system (TPS) RayStation and next-generation oncology information system (OIS) RayCare an at the University hospital of Leuven in Belgium, where patient treatments began in July.
 
Olivier Legrain, Chief Executive Officer of IBA commented: “We are immensely proud that IBA’s technology has now impacted over 100,000 lives, giving patients and their families a new hope for the future. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. Our philosophy of openly sharing our technological expertise with our clinical and industrial partners makes us uniquely positioned to speed up the development and shape the future of proton therapy.”

For more information: www.iba-worldwide.com

Related Content

During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from...
Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020
November 2, 2020 — An analysis of the...
Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

News | Radiation Therapy | November 02, 2020
November 2, 2020 — A nonsurgical treatment option for...